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Background: Chronic kidney disease (CKD) is a progressive and usually irreversible disease. Different types of
outcomes are of interest in the course of CKD such as time-to-dialysis, transplantation or decline of the glomerular
filtration rate (GFR). Statistical analyses aiming at investigating the association between these outcomes and risk
factors raise a number of methodological issues. The objective of this study was to give an overview of these
issues and to highlight some statistical methods that can address these topics.
Methods: A literature review of statistical methods published between 2002 and 2012 to investigate risk factors
of CKD outcomes was conducted within the Scopus database. The results of the review were used to identify
important methodological issues as well as to discuss solutions for each type of CKD outcome.
Results: Three hundred and four papers were selected. Time-to-event outcomes were more often investigated than
quantitative outcome variables measuring kidney function over time. The most frequently investigated events in
survival analyses were all-cause death, initiation of kidney replacement therapy, and progression to a specific value
of GFR. While competing risks were commonly accounted for, interval censoring was rarely acknowledged when
appropriate despite existing methods. When the outcome of interest was the quantitative decline of kidney
function over time, standard linear models focussing on the slope of GFR over time were almost as often used
as linear mixed models which allow various numbers of repeated measurements of kidney function per patient.
Informative dropout was accounted for in some of these longitudinal analyses.
Conclusions: This study provides a broad overview of the statistical methods used in the last ten years for
investigating risk factors of CKD progression, as well as a discussion of their limitations. Some existing potential
alternatives that have been proposed in the context of CKD or in other contexts are also highlighted.
Keywords: Kidney disease, Progression, ESRD, Survival analysis, Competing risks, Interval censoring, Multistate model,
Longitudinal analysis, Mixed modelsBackground
Chronic kidney disease (CKD) is a general term for het-
erogeneous disorders affecting the structure and function
of the kidney [1,2]. It usually follows a progressive course
and is hardly reversible (Figure 1). There is a need for
identification of risk factors of progression of CKD to
allow for potential therapeutic interventions. In particular,
progression to kidney failure, i.e. a glomerular filtration
rate (GFR) of less than 15 mL/min/1.73 m2 or the need* Correspondence: karen.leffondré@isped.u-bordeaux2.fr
1University of Bordeaux, ISPED, Centre INSERM U897-Epidemiology-Biostatistics,
Bordeaux F33000, France
Full list of author information is available at the end of the article
© 2014 Boucquemont et al.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumfor treatment with dialysis or transplantation, needs to be
prevented because of increased mortality and treatment
costs [1].
Various types of outcome variables can be used in the
statistical analysis when investigating risk factors associ-
ated with CKD progression. For example, the outcome
variable can be the time to progression to a specific
value of GFR, to initiation of dialysis or transplantation,
to cardiovascular events, or to all-cause death. The out-
come variable can also be the slope of decline in GFR,
or its overall trajectory over time.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Figure 1 Course of chronic kidney disease for a hypothetical patient with seven measurements of GFR (dots).
Boucquemont et al. BMC Nephrology 2014, 15:45 Page 2 of 12
http://www.biomedcentral.com/1471-2369/15/45If the outcome variable is the time to a particular
event of interest, then a survival regression model such
as the Cox model may seem obvious to investigate risk
factors associated with this event [3]. Standard survival
analysis requires the time-to-event to be known exactly
for all patients who experience the event. This is the
case, e.g. for events such as death or initiation of kidney
replacement therapy, where the exact dates can usually
be retrieved. However, the time-to-event may not be
exactly known for many other events of interest of kid-
ney disease progression. For example, the progression to
a specific value of GFR is known only to have occurred
between two consecutive measurements of GFR. In
such a situation, the time to progression to this value
is said to be ‘interval censored’ between the times of
these two measurements. Interval censoring should
ideally be accounted for in the analysis, especially if
the time interval between consecutive measurements
is long [4,5]. In addition, survival analysis may have
to account for competing risks. A competing event is
by definition an event which hinders the observation
of the event of interest [6,7]. For example, death is a
competing event for any event of progression since
patients who die during follow-up can no longer pro-
gress after death [8].
If the outcome of interest is the quantitative decline of
GFR over time, a linear regression model can be used to
investigate the association between risk factors and sum-
mary statistics (such as slopes) of the individual evolution
of GFR over time. However, such approaches often do
not account for all the information available on the
repeated measurements of kidney function, and imposesome assumptions that may not be valid. A linear mixed
model which uses all the repeated quantitative measure-
ments of kidney function may be preferable if there is a
sufficient number of patients with at least three measure-
ments [9]. This regression model accounts for correlation
between repeated measurements of the same patient, and
handles different numbers of measurements per patient
that may be measured at unequally spaced intervals, as
well as non-linear trajectories over time [10].
Each type of CKD outcome variable thus raises a num-
ber of methodological issues in the statistical analysis
investigating risk factors. Some of these statistical issues
have been acknowledged in the nephrology literature but
to our knowledge, no paper gives an overview of these
statistical issues. Thus, this paper attempts to provide
this overview and to highlight some methods that could
address these issues and that have been proposed in the
context of CKD or in some other contexts. To this end,
we first conducted a literature review of the statistical
methods that have been used in the last ten years to in-
vestigate risk factors of CKD outcomes. Second, we used
the results of this literature review to identify important
methodological issues and to highlight some methods
that address these issues. The methods used to perform
the literature review are described in the next section. In
the subsequent results section, we first describe the major
CKD outcomes that have been investigated in selected
papers, and then describe and discuss the regression
methods used for each type of outcomes. Where appro-
priate, we present some potential alternative analytical
approaches that have been never or rarely used in the con-
text of CKD but could yet be of interest.
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To identify the outcome variables and statistical methods
commonly used to investigate the effects of risk factors on
progression of CKD, we conducted a literature review
restricted to papers written in English language and pub-
lished from January 2002 to October 1st, 2012. We used
the Scopus database because it covers a wider range of
peer-reviewed journals than most other databases [11].
We performed two searches. Search 1 focused on epide-
miological studies (experimental or not) of CKD progres-
sion, while Search 2 focused on developments of new
statistical methods with application in the field of nephrol-
ogy. We searched for the same terms in Searches 1 and 2
but we specified different positions of these terms in the
papers. Specifically, one of the selected CKD terms (see
Table 1) had to appear in the title for Search 1; and in theTable 1 Terms used in our review to identify statistical
methods used to investigate risk factors of CKD outcomes
General
topic
Specific terms used Position in the
paper
CKD • Chronic kidney disease, CKD Title in Search 1
• Kidney function, renal function
• Glomerular filtration rate, GFR Title, key words or
abstract in Search 2
• Albuminuria, proteinuria
• Kidney disease, renal disease




• Proportional hazard(s), Cox, time-to-
event analysis(es), accelerated
failure time
Title, key words or
abstract in Search 1
• Frailty, shared Title in Search 2
• Competing
• Joint
• Linear regression(s), linear model(s)
• Logistic regression(s), logistic
model(s)
• Generalized, GEE
• Mixed model(s), mixed effect(s)
• Poisson













Abbreviations: CKD chronic kidney disease, GFR glomerular filtration rate, ESRD
end-stage renal disease, GEE generalized estimating equations, GMM growth
mixture model.title, key words, or abstract for Search 2. Selected terms
on statistical methods (Table 1) had to appear in either
the title, keywords, or abstract for Search 1, while they
had to appear in the title for Search 2. To decrease the
number of papers in Search 1 and to focus on papers in-
vestigating risk factors of CKD outcomes, epidemiological
terms on the study design were also required to appear in
addition to the keywords of Search 1 (Table 1). To avoid
duplication of papers, Search 2 was restricted to papers
not identified in Search 1.
We screened the titles and abstracts of all articles
resulting from Searches 1 and 2 to include papers only if
they investigated risk factors for progression of CKD. Pa-
pers were excluded if they investigated only (i) non CKD
outcomes in patients with kidney disease or outcomes
occurring after kidney replacement therapy only, (ii) non
CKD patients (such as patients with acute kidney injury),
(iii) kidney disease or renal function as a risk factor for an-
other disease, (iv) performance of equations used to esti-
mate GFR, or (v) risk factors for incidence or prevalence
of kidney disease without notion of progression thereafter,
or (vi) for other specific reasons (case analysis, economy,
chemistry, study/program design, sociology, fundamental
sciences, risk prediction, description of population).
For each of the selected articles, we retrieved the out-
come variables and the statistical method used to inves-
tigate risk factors associated with these outcomes.
Results and discussion
Search 1 resulted in 2384 papers, and Search 2 identified
613 additional papers. The title and abstract of all 2997
papers were further screened for inclusion and exclusion
criteria mentioned in the method section. This resulted in
304 articles that were finally selected for review (Figure 2).
See the Additional file 1 for the complete reference list of
the 304 selected papers.
Most papers were published in nephrology journals
(69%): Nephrology Dialysis Transplantation (20%), the
American Journal of Kidney Disease (18%), the Clinical
Journal of the American Society of Nephrology (13%),
Kidney International (12%) and the Journal of the American
Society of Nephrology (11%). Other papers were published
in general medical journals (8.5%), journals devoted to
cardiology (5.6%), diabetes (3.3%), statistical methods (3%),
HIV-AIDS (1.3%), and transplantation (0.3%). The few re-
maining were selected from journals devoted to other
specific subjects (e.g. gerontology, nutrition, pharmaco-
epidemiology).
Major outcomes used in the selected papers
The major outcomes investigated in the 304 selected
papers are described in first column of Table 2 for time-to-
event outcomes and of Table 3 for quantitative repeated
measurements of kidney function. The second column of
Figure 2 Flow diagram of selected articles.
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among the 304 papers. The sum of occurrences exceeds
304 because many papers investigated several outcomes.
Time-to-event outcomes were separated into three
subgroups. A first subgroup was comprised of outcomes
for which the time-to-event was known exactly (n = 307
occurrences, Table 2). A second subgroup was comprised
of outcomes for which the time-to-event was interval cen-
sored between two consecutive measurements of kidney
function (n = 45). A third subgroup comprised time-to-
event outcomes combining at least one event for which
time-to-event was exactly known and one event for which
time-to-event was interval censored (n = 43). Many papers
mentioned incidence of end-stage renal disease (ESRD) as
the event of interest. However, the definition of ESRD var-
ied across the papers. While in some papers incidence of
ESRD was defined as the initiation of kidney replacement
therapy (either dialysis or transplantation, whichever came
first), others defined it as the initiation of dialysis only,
transplantation only, death due to kidney failure only, or
any of these events whichever came first. Overall, all of
the events for which dates were known exactly were in-
vestigated on 83 occasions (Table 2). Initiation of kidney
replacement therapy or all-cause death, whichever came
first, was investigated on 38 occasions (Table 2). When
ESRD was defined as a GFR < 15 ml/min/1.73 m2, time-
to-event was interval-censored between two consecutive
measurements of GFR, and was then classified into
the second or third subgroup of events, depending on
whether it was combined or not with another event for
which the date was known exactly such as initiation ofkidney replacement therapy (Table 2). The most frequent
event in the second subgroup was an absolute or a relative
decrease in GFR superior to a specific value, compared
with the baseline GFR value (n = 19, Table 2).
In the 304 selected papers, the quantitative measure-
ment of kidney function over time was the outcome of
interest on 93 occasions (Table 3). The most frequently
investigated measurement was GFR (n = 78 occurrences)
but authors also investigated creatinine (n = 8) or protein-
uria (n = 7). While all individual repeated measurements
of the kidney function over time were used on 48 occa-
sions, a summary statistic such as the individual slope of
the marker over time was used as the outcome variable on
45 occasions (Table 3).
Regression methods used in the selected papers and
related statistical issues
The regression methods used for each outcome are
reported in the third column of Tables 2 and 3. The
last column indicates the occurrence and percentage
of the use of the regression method among the papers
investigating the specific outcome. The papers that
used each of the specific regression models are listed
in Table 2 available in the Additional file 1. Below, we
describe these methods and discuss potential issues
and alternative methods that have been proposed in
the context of CKD or in other contexts. Further-
more, Table 4 provides a list of some statistical procedures
that are available in SAS, R, or STATA software to
perform the most advanced statistical analyses dis-
cussed below.
Table 2 Frequency of survival (Cox, cause-specific, or Fine and Gray) and logistic regression models used to investigate
risk factors of time-to-event outcomes
Outcome investigated na Regression model mentioned in the paper n (%)b
Exactly known time-to-event 307
All-cause death 132 Cox model 108 (81.8)
Cause-specific model 10 (7.6)
Fine and Gray model 10 (7.6)
Logistic model 4 (3.0)
Cardiovascular death 31 Cox model 29 (93.6)
Cause-specific model 1 (3.2)
Fine and Gray model 1 (3.2)
Cardiovascular event 23 Cox model 23 (100.0)
Initiation of kidney replacement therapy or death due to kidney failure 83 Cox model 65 (78.3)
Fine and Gray model 10 (12.1)
Cause-specific model 7 (8.4)
Logistic model 1 (1.2)
Initiation of kidney replacement therapy or death (whichever comes first) 38 Cox model 38 (100.0)
Interval-censored time-to-event 45
Absolute or relative change in renal function higher than a specific value
as compared to baseline value, based on
23 Cox model 7 (30.4)
Fine and Gray model 1 (4.4)
- GFR (n = 19) Logistic model 15 (65.2)
- creatinine clearance (n = 3)
- proteinuria (n = 1)
Transition to a specific stage of disease, based on 13 Cox model 9 (69.2)
- GFR (n = 9) Logistic model 4 (30.8)
- proteinuria (n = 4)
Doubling of creatinine (serum or clearance) 8 Cox model 7 (87.5)
Logistic model 1 (12.5)
Composite of 1 Cox model 1 (100.0)
- decline in 30% of creatinine clearance
- increase in proteinuria > 3.5 g/d
Composite of exact and interval-censored time-to- events 43 Cox model 35 (81.4)
Fine and Gray model 3 (7.0)
Cause-specific model 3 (7.0)
Logistic model 2 (4.6)
Abbreviations: GFR glomerular filtration rate, CKD chronic kidney disease.
aNumber of occurrences the specific outcome was used. The total exceeds 304 because some papers investigated several types of events.
bNumber and percentage of occurrences the statistical method was used for each specific outcome.
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Only few analyses used logistic regression for time-to-
event outcomes, except when investigators considered a
specific absolute or relative change in renal function
over a given period of time as an event of interest (n = 15
occurrences, 65.2%, Table 2). Logistic regression analysis
assumes no drop-out due to loss-to-follow-up or death
during that period of time. The most popular method to
account for individual follow-up times was the standard
survival Cox model, as expected. For example, on the 132occurrences where all-cause death was investigated, the
Cox model was mentioned 108 (81.8%) times. Among the
83 occurrences where initiation of kidney replacement
therapy or death due to kidney failure was investigated,
the Cox model was mentioned 65 (78.3%) times.
Accounting for competing risks The cause-specific pro-
portional hazards model and the Fine and Gray model
(also called proportional subdistribution hazards model)
are two regression methods often used to account for
Table 3 Frequency of standard linear, linear mixed, and generalized estimating equations regression models to
investigate repeated measurements of renal function
Outcome investigated na Regression model mentioned in the paper n (%)b
All repeated measurements of renal function 48
Repeated measurements of 36 Linear mixed model 22 (61.1)
- GFR (n = 33) Linear mixed model accounting for informative 8 (22.2)
- Creatinine clearance (n = 2) drop-out
- Proteinuria (n = 1) Linear GEE 4 (11.1)
Linear GEE accounting for informative drop-out 1 (2.8)
Latent class growth analysis 1 (2.8)
Repeated measurements of 10 Linear mixed model 7 (70.0)
- log GFR (n = 5) Linear GEE 2 (20.0)
- log creatinine (serum or clearance) (n = 2) Latent class growth analysis 1 (10.0)
- log proteinuria (n = 3)
Absolute GFR change between each visit and baseline 1 Linear mixed model 1 (100.0)
Relative GFR change each year 1 Linear GEE 1 (100.0)
A summary statistic for the change of renal function 45
Individual slopec of 36 Linear model 36 (100.0)
- GFR (n = 30)
- Creatinine (serum or clearance) (n = 4)
- UACR (n = 2)
Absolute GFR change as compared to baseline 7 Linear model 7 (100.0)
Relative GFR change as compared to baseline 1 Linear model 1 (100.0)
Log of absolute proteinuria change as compared to baseline 1 Linear model 1 (100.0)
Abbreviations: GFR glomerular filtration rate, GEE generalized estimating equations, UACR urine albumin-to-creatinine ratio.
aNumber of occurrences the specific outcome was used. The total exceeds 304 because some papers investigated several types of outcomes.
bNumber and percentage of occurrences the statistical method was used for each specific outcome.
cSlope of a marker is a summary statistic derived from measurements of a patient.
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studies investigating risk factors of all-cause death, these
competing risks models were used 20 times (15.2%) to
account for initiation of kidney replacement therapy (see
e.g. [8,13,14]). If one wants to investigate risk factors of
all-cause death, kidney replacement therapy can indeed be
considered a competing event if one is interested in all-
cause-death before kidney replacement therapy. The cause-
specific proportional hazards model and the Fine and Gray
model were also used to account for death in studies
exploring factors associated with initiation of kidney
replacement therapy (n = 17, 20.5%) because patients who
die before initiation of therapy can no longer initiate
therapy after death.
In the cause-specific proportional hazards model, the
time-to-event of interest for patients who experience the
competing event is censored at the time of the compet-
ing event occurred, if the latter occurs before the event
of interest. Any software that handles the Cox model
can be used to estimate a cause-specific proportional haz-
ards model, as indicated in Table 4. The only requirementis to provide correct time-to-censoring for patients who
experience the competing event before the event of inter-
est. Many of the papers which mentioned the use of the
Cox model actually used a cause-specific proportional
hazards model. For example, on the 108 occurrences where
authors mentioned the use of the Cox model to investigate
risk factors of all-cause death, censoring at initiation of
kidney replacement therapy was reported on 26 occasions
(24.1%). On the 65 occurrences where authors mentioned
the use of the Cox model to investigate factors associated
with initiation of kidney replacement therapy, censoring at
death was reported on 32 occasions (49.2%). Similar results
were observed for other time-to-event outcomes. Compet-
ing risks were thus taken into account more frequently
than what Table 2 may suggest at first glance. The major
advantage of the cause-specific proportional hazards model
is that regression coefficients have a hazard (i.e. rate) ratio
interpretation [6,12,15], which is useful to study the
aetiology of diseases.
In contrast to the cause-specific proportional haz-
ards model, in the Fine and Gray model, patients who
Table 4 Examples of available software that handle





Survival regression models PROC PHREG survival stcox
Competing risks models
Cause-specific model PROC PHREG survival stcox
Fine and Gray model PSHREG macro cmprsk stcrreg















PROC GENMOD gee xtgee
geepack
yags
Mixed models PROC GLIMMIX lme xtmixed
PROC MIXED glmer GLLAMM
PROC NLMIXED
Identification of subpopulation of trajectories
Latent class growth analysis PROC TRAJ





PROC NLMIXED jm jmre1
CGEE2 macro
Joint latent class models lcmm
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the risk sets even after the competing event occurred, with
decreasing weights over time. Therefore, the regression
coefficients do not have a rate ratio interpretation. How-
ever, they are useful for prediction since they have a direct
relationship with the cumulative incidence functions which
measure the risk (i.e. probability) of an event within a given
time interval [6,12,15]. The Fine and Gray model is imple-
mented in several statistical packages (see e.g. the SAS
PHSREG macro [16]) as indicated in Table 4.Some alternatives to the cause-specific proportional
hazards model and to the Fine and Gray model have
been proposed and used in the context of CKD. For ex-
ample, Cianciaruso et al. [17] used a marginal competing
risks model and Scolari et al. [18] used a frailty model to
account for the correlation between ESRD and death
times [19]. However, it should be mentioned that inde-
pendence of competing risks is not needed for a valid
inference of the cause-specific model [15].
All the competing risk analyses mentioned above
require both the time-to-event of interest and the time-
to-competing event to be known exactly. While this usu-
ally holds for the time to initiation of renal replacement
therapy and the time to death, this is never the case for
the time to a specific stage of CKD based on GFR meas-
urement as discussed in the two following subsections.
Accounting for interval censoring As mentioned in
the introduction, interval censoring occurs in survival
analysis when the event of interest is lacking a precise
date and is only known to have occurred between two
dates [4,20]. For example, if the event of interest is transi-
tion to stage 3a of CKD, i.e. a GFR falling below 60 mL/
min/1.73 m2 (see Figure 1), the time to event is interval
censored between the last measurement with a GFR above
60 mL/min/1.73 m2 and the first measurement with a
GFR below 60 mL/min/1.73 m2. For example, for our
hypothetical patient, we only know that progression to
stage 3a occurred between his or her third and fourth
GFR measurement. Of the 24 occurrences where the Cox
model was used to investigate risk factors of a single
interval-censored time-to-event (Table 2), the interval
censoring issue was never acknowledged. Authors actually
imputed the time-to-event by the time to the first meas-
urement where the marker was below the specific level of
interest (e.g. 60 mL/min/1.73 m2 for GFR), or did not
specify how they imputed it. Yet such imputation may
produce biased estimates of risk factor effects and stand-
ard errors if the time intervals between consecutive mea-
surements are long, as they can be for some patients (see
e.g. [21-23]). The interval censoring issue has already been
acknowledged in the context of CKD, as in Bilous et al.,
for example, who studied incidence of micro-albuminuria
[20]. Several estimation methods handling interval censor-
ing are now available in different statistical software (see
Table 4), which should encourage investigators to account
for this issue in their analyses. However, interval censoring
further complicates competing risks analyses as discussed
in the next subsection.
Accounting both for competing risks and interval
censoring - multistate approach If one wants to inves-
tigate risk factors of progression to a specific stage of
CKD based on GFR measurement, e.g. progression to
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soring of the time-to-progression and competition with
death. In the cause-specific hazards model, the time to
stage 3a should be censored at the time of death for
patients who die before being diagnosed with a GFR
below 60 mL/min/1.73 m2. However, the GFR level at
death is usually unknown. Only the last GFR measure-
ment before death is known to be higher than 60 mL/
min/1.73 m2. Thus, it is uncertain whether the patient
had or had not progressed to stage 3a between the last
measurement and death. While censoring at death is
likely to produce bias because it assumes that the patient
did not progress to stage 3a between the last GFR meas-
urement and death, censoring at the last measurement
before death might not be a better solution. Indeed, a
simulation study has recently shown that censoring
either at death or at the last visit produces biased
estimates of the effect of factors that are associated with
the competing event (death) [24].
An alternative regression method that accounts for the
probability to progress to the specific CKD stage of
interest between the last measurement of renal function
and death or latest follow-up on vital status, is the illness-
death model for interval-censored data [5,24]. The illness-
death model is a specific multistate model with three
states [25]. Consider a hypothetical study where patients
would be in CKD stages 1 or 2 at baseline, and the out-
come of interest would be transition to stage 3a with
death as a competing event. The three states in the
illness-death model would be stages 1–2 of CKD (State 0),
stage 3a of CKD (State 1), and death (State 2). Using an
illness-death model for interval-censored data as the
one implemented in the SmoothHazard R package
[26] (Table 4) would allow us to account for the fact
that patients in the initial state 0 at the last measure-
ment before death may have progressed through the
intermediate state 1 of interest before dying. Such a flexi-
bility has been shown to produce accurate estimations of
the effects of factors on the state of interest [24]. However,
note that this model requires follow-up information on
vital status after transition to the specific stage of interest.
When more than one stage is of interest (for example,
if one wants to study all stages of CKD) and the follow-
up is long enough to ensure a sufficient number of
patients observed at different stages of the disease, even
more complex multistate models can be used. For ex-
ample, Begun et al. recently considered a six-state model
for interval-censored data, where the states were CKD
stages 3, 4 and 5, dialysis, transplant, and death [27]. Fou-
cher et al. proposed four-state and five-state models for
the study of kidney transplant evolution [4,28], consider-
ing interval-censored data since intermediate states were
defined on creatinine clearance and/or proteinuria levels.
Hu et al. also proposed a multistate approach to estimatethe probabilities to be in CKD stages 1–2, 3 and 4, dialysis,
or death before dialysis at different time points, while
accounting for the fact that estimated GFR was measured
at some specific time points only [29]. Multistate models
are now implemented in several statistical software such
as the R package mstate [30] (Table 4). However, when the
time to progression to some states is interval censored,
which is typically the case for the time to all intermediate
CKD stages, the estimation procedure is much more com-
plex. Indeed, the states are observed only at some points
in time and thus all possible transitions between these
time points need to be considered. To our knowledge,
only the msm R package [31] handles general multistate
models for interval-censored data (Table 4).
Quantitative outcome variables measuring kidney function
over time
Using a single summary statistic as the outcome vari-
able Among the 45 occurrences where the outcome
variable was a summary statistic of the renal function
decline over time, individual slope of GFR was used on
36 occasions, and individual change in GFR compared
to baseline was used on 7 occasions. All these analyses
consist of two steps. In step 1 the summary statistic for
each patient is derived, and step 2 uses this summary
statistic as the outcome variable in a linear regression to
investigate the association with patients’ characteristics
at baseline (Table 3). As mentioned by Rosansky [32],
using the slope of renal function for measuring renal tra-
jectory may be considered as “a starting point in applica-
tion of renal trajectory to clinical management”. However,
the two-step approach mentioned above is not the best
statistical approach to achieve this objective. Indeed, it has
numerous disadvantages including an important loss of
information [33], especially if individual values of the sum-
mary statistic (e.g. slope) are not first estimated using all
available measurements per patient or if many patients
have only a single measurement of the renal function.
Another important issue for statistical inference is that
Step 2 does not account for uncertainty of the summary
statistic derived in Step 1. Yet, the summary statistic (e.g.
slope) is an estimate, and the accuracy of this estimate for
a given patient strongly depends on the number of mea-
surements available for that patient, as well as the time
points at which these measurements were taken [34].
Ignoring such uncertainty is likely to produce unreliable
confidence intervals of the effect of the risk factor on the
slope. Finally, using the slope makes the implicit assump-
tion of a linear trajectory of the quantitative marker for
each individual, although this may not apply to a large
number of CKD patients [35]. Among the 36 occurrences
where the slope was used as the summary statistic, 16
(44.4%) had three or more repeated measurements of renal
function per patient, which would have made it possible to
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the next section.
Using all information and accounting for correlation
within individual repeated measurements of the renal
function – linear mixed models and GEE Two types
of regression models directly handle outcome variables
that have several observed values per subject: mixed
models and population average models estimated by
generalized estimating equations (GEE; also known as
the marginal approach). The effects of the factors on the
mean trajectory are estimated in one step only, without
the need to first derive a summary statistic for each
patient. Of the 48 occurrences where all repeated quan-
titative measurements of renal function were used as the
outcome variable, authors mainly used linear mixed
models (n = 38, 79.2%) (see e.g. [9,17,36,37]) to investi-
gate risk factors associated with the outcome. The term
mixed models refers to the use of both fixed and ran-
dom effects in the model. Random effects are used in
mixed models to represent variability between patients’
trajectories and to account for correlation between mea-
surements of a same patient. Indeed, this correlation
between repeated measurements has to be taken into
account for valid inference [10]. The major advantage of
linear mixed models is that they require neither equally
spaced time intervals between consecutive measure-
ments, nor the same number of measurements per pa-
tient. As a result, all available information is used in the
estimation process, including patients who have only
one available measurement of the outcome. This optimal
use of information allows more accurate estimates of the
effects of risk factors on the trajectory. Linear mixed
models can also handle nonlinear mean trajectories over
time of the marker.
On eight occasions (21.1%), authors used GEE (see e.g.
[38]). As all regression models, GEE handles any kind of
explanatory variables (see [39] for a general discussion
of representation of explanatory variables in regression
models). As mixed models, GEE account for correlations
between repeated measurements of a same patient [33].
When used to model individual repeated values of a
quantitative marker of the renal function, both linear
mixed models and linear GEE can be used to investigate
risk factors associated with the mean trajectory of the
marker over time. The estimation method differs, but in
the context of linear models, they should yield to very
similar estimates of risk factor effects, provided the set
of covariates as well as the correlation structure between
repeated measurements are equivalent in both approa-
ches. However, as opposed to standard mixed models,
standard GEE assumes that any study dropouts are
completely random. This assumption does not hold if
some patients are early dropouts because of dialysis ortransplantation. Indeed, such a dropout is not com-
pletely random since it is highly related to the rate of de-
cline in GFR [40] (see section on informative dropout).
In addition, because mixed models allow the modelling
of individual trajectories over time (via random effects),
they are more appropriate to perform individual predic-
tion than GEE. Indeed, GEE do not model individual
departure from the average trajectory over time. Mixed
models may thus be more interesting in a clinical set-
ting. Both methods are implemented in most standard
statistical software (Table 4). However, mixed models
may appear to be more complicated to use than GEE
because of the need to understand the concept of ran-
dom effects, and the need to specify their distribution.
Misspecification of the random effect distribution may
in some situations bias the results, but some solutions
have been proposed and applied to CKD data [41].
Accounting for non-normality of the measurements
of the renal function When using standard techniques
to estimate linear models, linear mixed models or linear
GEE, one of the four fundamental assumptions is the
normal distribution of errors. This assumption of nor-
mality must be checked on the distribution of the resid-
uals from the estimated model [42]. If this assumption
does not hold, a suitable transformation of the outcome
may be needed. Of the 91 occasions where the outcome
of interest was a quantitative measurement of the renal
function, a log-transformation of the measurement (GFR,
creatinine, proteinuria, or proteinuria change) was used
on 11 occasions for this reason. However, the regression
coefficients have a different interpretation after such a
transformation of the outcome variable since they meas-
ure the impact of risk factors on the log of the renal func-
tion, and not directly on the renal function. Furthermore,
the results of the linear model or the linear mixed model
may be robust to some departure from normal distribu-
tion, especially for large sample sizes [43]. In some situa-
tions, one may therefore have interest in not transforming
the measurement of kidney function in order to facilitate
interpretation and comparison of results between studies.
Investigating subpopulations of trajectories of the
quantitative marker The linear mixed model or the
population average model estimated by GEE assumes a
homogeneous population, i.e. only one mean trajectory
within the population. In CKD, several studies have shown
that the assumption of only one homogeneous population
in terms of renal function trajectory over time could be
too strong. For example, Li et al. have recently shown that
not all patients with CKD have a steady GFR progression
over time [35]. Different statistical methods can be used
to identify subpopulations with distinct trajectories of
renal function and to identify factors discriminating these
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GFR courses over time between different groups of albu-
minuric patients using functional data analysis for longitu-
dinal data [44]. O’Hare et al. studied trajectories of GFR
using a latent class growth analysis, implemented in the
SAS PROC TRAJ [45]. De Beaudrap et al. also used a
latent class growth analysis but with the log of GFR as the
outcome to achieve normality [9]. Briefly, the latent class
growth analysis allows identification of classes of individ-
uals following similar progressions of the outcome over
time [46]. However, this method assumes no individual
deviation from the class mean trajectory, and independ-
ence of repeated measurements of a same patient within
the class [47]. An alternative method which does not have
these limitations and has already been used in some con-
texts other than CKD is the latent class linear mixed
model, also called growth mixture modelling [48-50]. Al-
though this model is more complex to estimate than the
more simple model in the latent class growth analysis,
some statistical software packages such as Mplus [47] or
the lcmm R package, are now available to perform such
analyses (Table 4). The lcmm package also handles joint
latent class models which may be used to account for
informative censoring as discussed below [51].
Accounting for informative censoring-joint models
An important issue in longitudinal analyses of a quanti-
tative marker of the renal function is early study dropout
[52] due to, e.g. initiation of kidney replacement therapy.
If the reason for dropout of the study is unrelated to
renal function, the data missing after each individual last
observed value of the marker are said to be “missing
completely random” (MCAR). In this situation, both
standard linear mixed models and standard linear GEE
can be used to investigate the effect of risk factors on
the mean trajectory of the renal function. If the reason
for dropout is associated only with previously observed
values of the marker (and not with unobserved values of
the renal function after dropout), missing data due to
dropout are said to be “missing at random” (MAR). In this
situation, standard linear mixed models or a weighted
version of GEE [53] can be used. However, if the reason
for dropout is related to non-observed values of the renal
function, missing data are said to be “non-random” or “in-
formative”, and the dropout process should be jointly
modelled with the marker of the renal function, or the
analysis should be performed conditionally on the pattern
of dropouts [54]. These approaches handling informative
censoring should therefore be used to investigate risk fac-
tors of GFR trajectory if some patients dropout of the
study because of kidney initiation therapy and one believes
that initiation depends not only on previous observed
values of GFR, but also on unobserved values of GFR. Out
of the 91 occurrences where the outcome of interest wasthe quantitative measurement of the renal function over
time, death or initiation of kidney replacement therapy (or
other medical reasons) has been acknowledged as a source
of informative censoring, and accounted for accordingly,
on nine occasions (9.9%) (see e.g. [55-58]).
Different statistical approaches have been proposed to
jointly model longitudinal quantitative markers and clin-
ical events. They consist of considering a model for the
renal function trajectory (usually a linear mixed model)
and a model for the time-to-death or kidney replace-
ment therapy (usually a Cox model), and linking both
models using a shared latent structure. The most popu-
lar joint modelling approach uses a shared random-
effects model. In a methodological paper, Vonesh et al.
proposed such an approach to analyse data from the
modification of diet in renal diseases (MDRD) study
[58], and provided some SAS code necessary to imple-
ment the method (Table 4). Shared random-effects
models are also implemented in the JM R package [59]
(Table 4). An alternative approach consists in using a
joint latent class model. As opposed to the first approach,
the joint latent class model assumes that the population is
divided into various subpopulations with different longitu-
dinal evolutions of the quantitative marker associated with
different risk functions for the event [51]. In the context
of CKD, such an approach has been proposed by Garre
et al. to jointly model the reciprocal of serum creatinine
and time to renal graft failure [60]. Joint latent class
models are implemented in the R package lcmm.
It should be noted that the joint modelling approach
can also be used for other purposes including account-
ing for the trajectory of the quantitative marker to dy-
namically predict the clinical event [51].
Conclusions
This paper provides an overview of the state of the art of
statistical regression methods used to investigate risk fac-
tors of CKD outcomes. Although our review is not an ex-
haustive review of all statistical methods used in this
context, we are confident that it highlights important stat-
istical issues in studies of risk factors of CKD progression
and discusses how they can be accounted for by using ap-
propriate existing methods. It should be mentioned that
because our aim was to provide an overview of regression
methods for investigating risk factors, so for aetiological
research, we did not focus our attention to studies aiming
at establishing risk prediction models. However, some of
the issues that we addressed in this paper also apply in the
context of prediction of CKD outcomes. For example,
competing risks should also be accounted for in this con-
text [61], and new metrics for the evaluation of prognosis
performance should be used [62].
As all overviews, our study is just an introduction to
issues that would all merit further discussion. On the
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only an overview can provide a picture of the connection
between them. In particular, interval censoring compli-
cates competing risks analyses of CKD progression, and
specific methods accounting for both issues should be
used, especially when investigating populations at rela-
tively high risk of dying and when the time interval be-
tween consecutive measurements of the renal function
may be long for some patients [24]. For longitudinal
analyses where the outcome of interest is the whole
trajectory of the renal function over time, we discussed
the need to use linear mixed models or GEE to account
for all the information available on the repeated mea-
surements of the renal function for each patient, as well
as to obtain reliable confidence intervals of risk factor
effects on the renal trajectory. We also highlighted some
methods to identify subpopulations with different trajec-
tories of renal function over time, as well as methods to
account for potential informative censoring due to death
or kidney replacement therapy. Investigators have to be
encouraged to account for these issues in statistical ana-
lyses, in order to obtain unbiased estimates of the effects
of risk factors on CKD progression.
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